The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease

British Journal of Pharmacology

Volumn , Issue , 2016, Pages 3041-3079

  Evans, James C ^a   Malhotra, Meenakshi ^a   Cryan, John F ^a   O'Driscoll, Caitriona M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; DOCETAXEL; DOXORUBICIN; GLUTAMATE CARBOXYPEPTIDASE II; METHOTREXATE; PREDNISONE; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; DRUG MECHANISM; HUMAN; IONIZING RADIATION; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW;

EID: 85027939727     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13576     Document Type: Review

References (272)

1. Abdel-Hadi M, Ismail Y, Younis L (2014). Prostate-specific membrane antigen (PSMA) immunoexpression in the neovasculature of colorectal carcinoma in Egyptian patients. Pathol Res Pract 210: 759–763.
2. Abdolahi M, Shahbazi-Gahrouei D, Laurent S, Sermeus C, Firozian F, Allen BJ et al. (2013). Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer. Contrast Media Mol Imaging 8: 175–184.
3. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M et al. (2015). The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42: 197–209.
4. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG et al. (2014). Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41: 11–20.
5. Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E et al. (2015). Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res 5: 1–8.
6. Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST (2011). Prostate-specific membrane antigen-based therapeutics. Adv Urol 2012. doi:10.1155/2012/973820.
7. Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
8. Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol 172: 5979–6023.
9. Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015c). The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5729–5743.
10. Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015d). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110–6202.
11. Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015e). The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. Br J Pharmacol 172: 5956–5978.
12. Anilkumar G, Barwe SP, Christiansen JJ, Rajasekaran SA, Kohn DB, Rajasekaran AK (2006). Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for targeting to tumor vasculature. Microvasc Res 72: 54–61.
13. Anilkumar G, Rajasekaran SA, Wang S, Hankinson O, Bander NH, Rajasekaran AK (2003). Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res 63: 2645–2648.
14. Apetoh L, Ladoire S, Coukos G, Ghiringhelli F (2015). Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol. doi:10.1093/annonc/mdv209.
15. Arndt C, Feldmann A, Koristka S, Cartellieri M, Dimmel M, Ehninger A et al. (2014). Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system. Prostate 74: 1335–1346.
16. Baek SE, Lee KH, Park YS, Oh D-K, Oh S, Kim K-S et al. (2014). RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo. J Control Release 196: 234–242.
17. Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R et al. (2007). Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 7: 3065–3070.
18. Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D et al. (2013). Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia 15: 1172–IN1132.
19. Bandari RP, Jiang Z, Reynolds TS, Bernskoetter NE, Szczodroski AF, Bassuner KJ et al. (2014). Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN (7-14) NH 2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer. Nucl Med Biol 41: 355–363.
20. Bandekar A, Zhu C, Jindal R, Bruchertseifer F, Morgenstern A, Sofou S (2014). Anti–prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer. J Nucl Med 55: 107–114.
21. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005). Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23: 4591–4601.
22. Banerjee SR, Foss CA, Pullambhatla M, Wang Y, Srinivasan S, Hobbs RF et al. (2015). Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates. J Nucl Med 56: 628–634.
23. Banerjee SR, Pullambhatla M, Foss CA, Nimmagadda S, Ferdani R, Anderson CJ et al. (2014). 64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem 57: 2657–2669.
24. Bařinka C, Rojas C, Slusher B, Pomper M (2012). Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem 19: 856.
25. Barinka C, Šácha P, Sklenář J, Man P, Bezouška K, Slusher BS et al. (2004). Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci 13: 1627–1635.
26. Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S et al. (2013). First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med 54: 380–387.
27. Baskar R, Lee KA, Yeo R, Yeoh K-W (2012). Cancer and radiation therapy: current advances and future directions. Int J Med Sci 9: 193.
28. Becker I, Lodder J, Gieselmann V, Eckhardt M (2010). Molecular characterization of N-acetylaspartylglutamate synthetase. J Biol Chem 285: 29156–29164.
29. Behe M, Alt K, Deininger F, Buehler P, Wetterauer U, Weber WA et al. (2011). In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer. In Vivo 25: 55–59.
30. Behnam Azad B, Banerjee SR, Pullambhatla M, Lacerda S, Foss CA, Wang Y et al. (2015). Evaluation of a PSMA-targeted BNF nanoparticle construct. Nanoscale 7: 4432–4442.
31. Berent-Spillson A, Robinson AM, Golovoy D, Slusher B, Rojas C, Russell JW (2004). Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3. J Neurochem 89: 90–99.
32. Bouchelouche K, Choyke PL, Capala J (2010). Prostate specific membrane antigen—a target for imaging and therapy with radionuclides. Discov Med 9: 55.
33. Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, Nicoletti F (1998). Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-β. J Neurosci 18: 9594–9600.
34. Cao Y, Gao Y, Xu S, Bao J, Lin Y, Luo X et al. (2016). Glutamate carboxypeptidase II gene knockout attenuates oxidative stress and cortical apoptosis after traumatic brain injury. BMC Neurosci 17: 1.
35. Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A et al. (2015). 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 42: 1284–1294.
36. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB (1999a). Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5: 2674–2681.
37. Chang SS, Reuter VE, Heston W, Bander NH, Grauer LS, Gaudin PB (1999b). Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59: 3192–3198.
38. Chang SS, Bander NH, Heston WD (2004). Biology of PSMA as a diagnostic and therapeutic target. In: Klein EA (ed.). Management of Prostate Cancer. Springer: Totowa, NJ, pp. 609–630.
39. Chang SS, Gaudin PB, Reuter VE, Heston WD (2000). Prostate-specific membrane antigen: present and future applications. Urology 55: 622–629.
40. Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, Koning GA, Boerman OC et al. (2015). A novel 111In-labeled anti-PSMA nanobody for targeted SPECT/CT imaging of prostate cancer. J Nucl Med 56: 1094–1099.
41. Chen R, Zhao Y, Huang Y, Yang Q, Zeng X, Jiang W et al. (2015). Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice. Prostate 75: 593–602.
42. Chen S-R, Wozniak KM, Slusher BS, Pan H-L (2002). Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. J Pharmacol Exp Ther 300: 662–667.
43. Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S et al. (2011). 2-(3-{1-Carboxy-5-[(6-[18F] fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid,[18F] DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 17: 7645–7653.
44. Chen Y, Wang G, Kong D, Zhang Z, Yang K, Liu R et al. (2013). Double-targeted and double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for prostate cancer. Mol Carcinog 52: 237–246.
45. Chen Z, Penet M-F, Nimmagadda S, Li C, Banerjee SR, Winnard PT Jr et al. (2012). PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano 6: 7752–7762.
46. Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A et al. (2012). Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 53: 1883–1891.
47. Choi J-Y, Kim J-H, Jo SA (2014). Acetylation regulates the stability of glutamate carboxypeptidase II protein in human astrocytes. Biochem Biophys Res Commun 450: 372–377.
48. Chu TC, Shieh F, Lavery LA, Levy M, Richards-Kortum R, Korgel BA et al. (2006). Labeling tumor cells with fluorescent nanocrystal–aptamer bioconjugates. Biosens Bioelectron 21: 1859–1866.
49. Conway RE, Joiner K, Patterson A, Bourgeois D, Rampp R, Hannah BC et al. (2013). Prostate specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2. Angiogenesis 16: 847–860.
50. Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH (2006). Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 26: 5310–5324.
51. Cooperberg MR, Broering JM, Carroll PR (2010). Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28: 1117–1123.
52. Coyle JT (1997). The nagging question of the function of N-acetylaspartylglutamate. Neurobiol Dis 4: 231–238.
53. Dachs GU, Tupper J, Tozer GM (2005). From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 16: 349–359.
54. Dassie JP, Hernandez LI, Thomas GS, Long ME, Rockey WM, Howell CA et al. (2014). Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen. Mol Ther 22: 1910–1922.
55. Dassie JP, X-y L, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR et al. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27: 839–846.
56. Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ (2005). Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci 102: 5981–5986.
57. De la Vieja A, Dohan O, Levy O, Carrasco N (2000). Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 80: 1083–1105.
58. Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S et al. (1996). Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 2: 1289–1297.
59. Delaney G, Jacob S, Featherstone C, Barton M (2006). The role of radiotherapy in cancer treatment: estimating optimal utilisation from a review of evidence-based guidelines. Cancer 104: 1129–1137.
60. Demirkol MO, Acar Ö, Uçar B, Ramazanoğlu SR, Sağlıcan Y, Esen T (2015). Prostate-specific membrane antigen-based imaging in prostate cancer: Impact on clinical decision making process. Prostate 75: 748–757.
61. Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I et al. (2012). Engineering a prostate-specific membrane antigen–activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 4: 140ra186–140ra186.
62. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC (2011). Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci 108: 1850–1855.
63. Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K et al. (2015). Comparison of [18F] DCFPyL and [68Ga] Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol 17: 575–584.
64. DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E (2015). Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. Prostate 75: 303–313.
65. Donovan JL (2012). Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/monitoring. J Natl Cancer Inst Monogr 2012: 191.
66. Du Y-F, Long Q-Z, Shi Y, Liu X-G, Li X-D, Zeng J et al. (2013). Prostate-targeted mTOR-shRNA inhibit prostate cancer cell growth in human tumor xenografts. Int J Clin Exp Med 6: 126.
67. Eder M, Schäfer M, Bauder-Wüst U, Haberkorn U, Eisenhut M, Kopka K (2014). Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate 74: 659–668.
68. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B et al. (2015). Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56: 668–674.
69. Eshhar Z (2008). The T-body approach: redirecting T cells with antibody specificity. In: Chernajovsky Y, Nissim A (eds). Therapeutic Antibodies. Springer: Berlin Heidelberg, pp. 329–342.
70. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH et al. (2002). Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 94: 981–990.
71. Evans J, McCarthy J, Torres-Fuentes C, Cryan J, Ogier J, Darcy R et al. (2015). Cyclodextrin mediated delivery of NF-κB and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro. Gene Ther 22: 802–810.
72. Fan X, Wang L, Guo Y, Tu Z, Li L, Tong H et al. (2015). Ultrasonic Nanobubbles carrying anti-psma nanobody: construction and application in prostate cancer-targeted imaging. PLoS One 10: e0127419.
73. Feng J-F, Van KC, Gurkoff GG, Kopriva C, Olszewski RT, Song M et al. (2011). Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI. Brain Res 1395: 62–73.
74. Ferraris DV, Shukla K, Tsukamoto T (2012). Structure–activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors. Curr Med Chem 19: 1282–1294.
75. Ferraro B, Cisper NJ, Talbott KT, Philipson-Weiner L, Lucke CE, Khan AS et al. (2011). Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses. Hum Vaccin 7 (Supp1): 120–127.
76. Fishman M (2009). A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin Biol Ther 9: 1565–1575.
77. Rahn KA, Slusher BS, Kaplin AI (2012). Glutamate in CNS neurodegeneration and cognition and its regulation by GCPII inhibition. Curr Med Chem 19: 1335–1345.
78. Fortmüller K, Alt K, Gierschner D, Wolf P, Baum V, Freudenberg N et al. (2011). Effective targeting of prostate cancer by lymphocytes redirected by a PSMA× CD3 bispecific single-chain diabody. Prostate 71: 588–596.
79. Fuessel S, Meye A, Schmitz M, Zastrow S, Linné C, Richter K et al. (2006). Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a phase I clinical trial. Prostate 66: 811–821.
80. Ganguly T, Dannoon S, Hopkins MR, Murphy S, Cahaya H, Blecha JE et al. (2015). A high-affinity [18 F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Nucl Med Biol 42: 780–787.
81. Gao X-F, Zhou T, Chen G-H, Xu C-L, Ding Y-L, Sun Y-H (2014). Radioiodine therapy for castration-resistant prostate cancer following prostate-specific membrane antigen promoter-mediated transfer of the human sodium iodide symporter. Asian J Androl 16: 120.
82. Ghadge GD, Slusher BS, Bodner A, Dal Canto M, Wozniak K, Thomas AG et al. (2003). Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci 100: 9554–9559.
83. Ghosh A, Heston WD (2005a). Understanding prostate-specific membrane antigen and its implication in prostate cancer. In: LaRochelle WJ, Shimkets RA (eds). The Oncogenomics Handbook. Springer: Totowa, NJ, pp. 597–615.
84. Ghosh A, Wang X, Klein E, Heston WD (2005b). Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res 65: 727–731.
85. Giesel FL, Fiedler H, Stefanova M, Sterzing F, Rius M, Kopka K et al. (2015). PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga (HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42: 1794–1800.
86. Goodman OB, Barwe SP, Ritter B, McPherson PS, Vasko A-J, Keen JH et al. (2007). Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2. Int J Oncol 31: 1199–1203.
87. Graham K, Lesche R, Gromov AV, Böhnke N, Schäfer M, Hassfeld J et al. (2012). Radiofluorinated derivatives of 2-(Phosphonomethyl) pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer. J Med Chem 55: 9510–9520.
88. Grimm D, Kay MA (2007). RNAi and gene therapy: a mutual attraction. Hematology Am Soc Hematol Educ Program 2007: 473–481.
89. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. (2013). Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509–1518.
90. Guilarte TR, Hammoud DA, McGlothan JL, Caffo BS, Foss CA, Kozikowski AP et al. (2008). Dysregulation of glutamate carboxypeptidase II in psychiatric disease. Schizophr Res 99: 324–332.
91. Guilarte TR, McGlothan JL, Foss CA, Zhou J, Heston WD, Kozikowski AP et al. (2005). Glutamate carboxypeptidase II levels in rodent brain using [125 I] DCIT quantitative autoradiography. Neurosci Lett 387: 141–144.
92. Guo H, Liu J, Van Shura K, Chen H, Flora MN, Myers TM et al. (2015). N-acetyl-aspartyl-glutamate and inhibition of glutamate carboxypeptidases protects against soman-induced neuropathology. Neurotoxicology 48: 180–191.
93. Guo J, Evans JC, O'Driscoll CM (2013a). Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer? Trends Mol Med 19: 250–261.
94. Guo Z, Huang H, Zeng L, Du T, Xu K, Lin T et al. (2011). Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells. Med Oncol 28: 878–887.
95. Guo Z, Lai Y, Zhang Y, Chen J, Bi L, Lin T et al. (2013b). Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway. Chin Med J (Engl) 127: 929–936.
96. Gurkoff GG, Feng J-F, Van KC, Izadi A, Ghiasvand R, Shahlaie K et al. (2013). NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia. Brain Res 1515: 98–107.
97. Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Mühlmann G et al. (2009). Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 40: 1754–1761.
98. Hao Z, Fan W, Hao J, Wu X, Zeng GQ, Zhang LJ et al. (2016). Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo. Drug Deliv 23: 864–871.
99. Hariri W, Sudha T, Bharali DJ, Cui H, Mousa SA (2015). Nano-targeted delivery of toremifene, an estrogen receptor-α blocker in prostate cancer. Pharm Res 32: 2764–2774.
100. Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN et al. (2013). 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med 54: 1369–1376.
101. Hlouchová K, Bařinka C, Klusák V, Šácha P, Mlčochová P, Majer P et al. (2007). Biochemical characterization of human glutamate carboxypeptidase III. J Neurochem 101: 682–696.
102. Horoszewicz JS, Kawinski E, Murphy G (1986). Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7: 927–935.
103. Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T et al. (2012). Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 4: 128ra139–128ra139.
104. Huang B, Otis J, Joice M, Kotlyar A, Thomas TP (2014). PSMA-targeted stably linked “dendrimer-glutamate urea-methotrexate” as a prostate cancer therapeutic. Biomacromolecules 15: 915–923.
105. Israeli RS, Powell CT, Fair WR, Heston WD (1993). Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53: 227–230.
106. Jackson AL, Linsley PS (2010). Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9: 57–67.
107. Jackson PF, Cole DC, Slusher BS, Stetz SL, Ross LE, Donzanti BA et al. (1996). Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated α-linked acidic dipeptidase. J Med Chem 39: 619–622.
108. Jackson SP, Bartek J (2009). The DNA-damage response in human biology and disease. Nature 461: 1071–1078.
109. Janczura KJ, Olszewski RT, Bzdega T, Bacich DJ, Heston WD, Neale JH (2013). NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test. Eur J Pharmacol 701: 27–32.
110. Jin J, Sui B, Gou J, Liu J, Tang X, Xu H et al. (2014). PSMA ligand conjugated PCL-PEG polymeric micelles targeted to prostate cancer cells.
111. Kahn D, Austin JC, Maguire RT, Miller SJ, Gerstbrein J, Williams RD (1999). A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. Cancer Biother Radiopharm 14: 99–111.
112. Kahn D, Williams RD, Haseman MK, Reed NL, Miller SJ, Gerstbrein J (1998a). Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 16: 284–289.
113. Kahn D, Williams RD, Manyak MJ, Haseman MK, Seldin DW, Libertino JA et al. (1998b). (111) Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol 159: 2041–2047.
114. Kampmeier F, Williams JD, Maher J, Mullen GE, Blower PJ (2014). Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA). EJNMMI Res 4: 13.
115. Kawabata H, Yang R, Hirama T, Vuong PT, Kawano S, Gombart AF et al. (1999). Molecular cloning of transferrin receptor 2 A new member of the transferrin receptor-like family. J Biol Chem 274: 20826–20832.
116. Khacho P, Wang B, Ahlskog N, Hristova E, Bergeron R (2015). Differential effects of N-acetyl-aspartyl-glutamate on synaptic and extrasynaptic NMDA receptors are subunit-and pH-dependent in the CA1 region of the mouse hippocampus. Neurobiol Dis 82: 580–592.
117. Kiess A, Minn I, Chen Y, Hobbs RF, Sgouros G, Mease RC et al. (2015). Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen. J Nucl Med 56: 1401–1407.
118. Kim E, Jung Y, Choi H, Yang J, Suh J-S, Huh Y-M et al. (2010). Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 31: 4592–4599.
119. Kim JS, Lee SD, Lee SJ, Chung MK (2013). Development of an immunotherapeutic adenovirus targeting hormone-independent prostate cancer. OncoTargets Ther 6: 1635.
120. Kozikowski AP, Nan F, Conti P, Zhang J, Ramadan E, Bzdega T et al. (2001). Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase)[1]. J Med Chem 44: 298–301.
121. Kozikowski AP, Zhang J, Nan F, Petukhov PA, Grajkowska E, Wroblewski JT et al. (2004). Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem 47: 1729–1738.
122. Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benešová M, Mier W et al. (2015). [177Lu] Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 42: 987–988.
123. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W et al. (2010). Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28: 2698–2704.
124. Larson SM, Carrasquillo JA, Cheung N-KV, Press OW (2015). Radioimmunotherapy of human tumours. Nat Rev Cancer 15: 347–360.
125. Lawrence CM, Ray S, Babyonyshev M, Galluser R, Borhani DW, Harrison SC (1999). Crystal structure of the ectodomain of human transferrin receptor. Science 286: 779–782.
126. Lee I-H, An S, Yu MK, Kwon H-K, Im S-H, Jon S (2011). Targeted chemoimmunotherapy using drug-loaded aptamer–dendrimer bioconjugates. J Control Release 155: 435–441.
127. Lesche R, Kettschau G, Gromov AV, Böhnke N, Borkowski S, Mönning U et al. (2014). Preclinical evaluation of BAY 1075553, a novel 18F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging 41: 89–101.
128. Lodder-Gadaczek J, Becker I, Gieselmann V, Wang-Eckhardt L, Eckhardt M (2011). N-acetylaspartylglutamate synthetase II synthesizes N-acetylaspartylglutamylglutamate. J Biol Chem 286: 16693–16706.
129. Lonergan PE, Tindall DJ (2011). Androgen receptor signaling in prostate cancer development and progression. J Carcinog 10: 20.
130. Long JB, Yourick DL, Slusher BS, Robinson MB, Meyerhoff JL (2005). Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats. Eur J Pharmacol 508: 115–122.
131. Łukawski K, Kamiński RM, Czuczwar SJ (2008). Effects of selective inhibition of N-acetylated-α-linked-acidic dipeptidase (NAALADase) on mice in learning and memory tasks. Eur J Pharmacol 579: 202–207.
132. Luthi-Carter R, Barczak AK, Speno H, Coyle JT (1998). Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II. Brain Res 795: 341–348.
133. Lütje S, Rijpkema M, Franssen GM, Fracasso G, Helfrich W, Eek A et al. (2014). Dual-modality image-guided surgery of prostate cancer with a radiolabeled fluorescent anti-PSMA monoclonal antibody. J Nucl Med 55: 995–1001.
134. Ma Q, Gomes EM, Lo ASY, Junghans RP (2014). Advanced generation anti-prostate specific membrane antigen designer T Cells for prostate cancer immunotherapy. Prostate 74: 286–296.
135. Mahadevan D, Saldanha JW (1999). The extracellular regions of PSMA and the transferrin receptor contain an aminopeptidase domain: implications for drug design. Protein Sci 8: 2546–2549.
136. Majer P, Jackson PF, Delahanty G, Grella BS, Ko Y-S, Li W et al. (2003). Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem 46: 1989–1996.
137. Majer P, Jančařík A, Krecmerova M, Tichý TS, Tenora LS, Wozniak K et al. (2016). Discovery of orally available prodrugs of the glutamate carboxypeptidase II (GCPII) inhibitor 2-phosphonomethylpentanedioic acid (2-PMPA). J Med Chem 59: 2810–2819.
138. Martin SE, Ganguly T, Munske GR, Fulton MD, Hopkins MR, Berkman CE et al. (2014). Development of inhibitor-directed enzyme prodrug therapy (IDEPT) for prostate cancer. Bioconjug Chem 25: 1752–1760.
139. Mazzaferri EL, Kloos R (1996). Carcinoma of follicular epithelium: radioiodine and other treatments and outcomes. In: Braverman LE, Utiger RD (eds). The Thyroid: A Fundamental and Clinical Text, Vol. 7. Philadelphia, PA, pp. 922–945.
140. McKinzie D, Li TK, McBride W, Slusher B (2000). NAALADase inhibition reduces alcohol consumption in the alcohol-preferring (P) line of rats. Addict Biol 5: 411–416.
141. Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS et al. (2006). Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 25: 1375–1384.
142. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ et al. (2007). Vascular targeted therapy with anti–prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 25: 540–547.
143. Morigi JJ, Stricker P, Van Leeuwen P, Tang R, Ho B, Nguyen Q et al. (2015). Prospective Comparison of the detection rate of18F-Fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative treatment, being considered for targeted therapy. J Nucl Med 56: 1185–1190.
144. Morris MJ, Pandit-Taskar N, Divgi CR, Bender S, O'Donoghue JA, Nacca A et al. (2007). Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res 13: 2707–2713.
145. Nagel J, Belozertseva I, Greco S, Kashkin V, Malyshkin A, Jirgensons A et al. (2006). Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain–relation to brain concentration. Neuropharmacology 51: 1163–1171.
146. Nan F, Bzdega T, Pshenichkin S, Wroblewski JT, Wroblewska B, Neale JH et al. (2000). Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity. J Med Chem 43: 772–774.
147. Navrátil M, Ptáček J, Šácha P, Starková J, Lubkowski J, Bařinka C et al. (2014). Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II. FEBS J 281: 3228–3242.
148. Navrátil M, Tykvart J, Schimer J, Pachl P, Navrátil V, Rokob TA et al. (2016). Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities. FEBS J 283: 2528–2545.
149. Neale JH, Bzdega T, Wroblewska B (2000). N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem 75: 443–452.
150. Neale JH, Olszewski RT, Zuo D, Janczura KJ, Profaci CP, Lavin KM et al. (2011). Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. J Neurochem 118: 490–498.
151. Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z et al. (2011). Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 121: 2383.
152. Nomura N, Pastorino S, Jiang P, Lambert G, Crawford JR, Gymnopoulos M et al. (2014). Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int 14: 26.
153. O'donoghue J, Bardies M, Wheldon T (1995). Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36: 1902–1909.
154. O'Keefe DS, Uchida A, Bacich DJ, Watt FB, Martorana A, Molloy PL et al. (2000). Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 45: 149–157.
155. O'Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT et al. (1998). Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta Gene Struct Expression 1443: 113–127.
156. Olszewski R, Janczura K, Ball S, Madore J, Lavin K, Lee JC et al. (2012). NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia. Transl Psychiatry 2: e145.
157. Olszewski RT, Bukhari N, Zhou J, Kozikowski AP, Wroblewski JT, Shamimi-Noori S et al. (2004). NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem 89: 876–885.
158. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST (2013). Prostate-specific membrane antigen-based imaging. Urol Oncol 31: 144–154.
159. Oser MG, Niederst MJ, Sequist LV, Engelman JA (2015). Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 16: e165–e172.
160. Palucka K, Banchereau J (2012). Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12: 265–277.
161. Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V et al. (2015a). A phase I/II study for analytic validation of 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer. Clin Cancer Res 21: 5277–5285.
162. Pandit-Taskar N, O'Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gönen M et al. (2015b). Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res 5: 1–13.
163. Pangalos MN, Neefs J-M, Somers M, Verhasselt P, Bekkers M, van der Helm L et al. (1999). Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated α-linked acidic dipeptidase and dipeptidyl peptidase IV activity. J Biol Chem 274: 8470–8483.
164. Peng Z-H, Sima M, Salama ME, Kopečková P, Kopeček J (2013). Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer. J Drug Target 21: 968–980.
165. Pérez-Herrero E, Fernández-Medarde A (2015). Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93: 52–79.
166. Pienta KJ, Bradley D (2006). Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12: 1665–1671.
167. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP et al. (1996). Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2: 1445–1451.
168. Pomper MG, Musachio JL, Zhang J, Scheffel U, Zhou Y, Hilton J et al. (2002). 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging 1: 96–101.
169. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011). Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725–733.
170. Potter MC, Wozniak KM, Callizot N, Slusher BS (2014). Glutamate carboxypeptidase II inhibition behaviorally and physiologically improves pyridoxine-induced neuropathy in rats. PLoS One 9: e102936.
171. Profaci CP, Krolikowski KA, Olszewski RT, Neale JH (2011). Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia. Psychopharmacology (Berl) 216: 235–243.
172. Rais R, Wozniak K, Wu Y, Niwa M, Stathis M, Alt J et al. (2015). Selective CNS uptake of the GCP-II inhibitor 2-PMPA following intranasal administration. PLoS One 10: e0131861.
173. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W et al. (2003). A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 14: 4835–4845.
174. Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S et al. (2013). Effect of chelators on the pharmacokinetics of 99mTc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). J Med Chem 56: 6108–6121.
175. Ren H, Zhang H, Wang X, Liu J, Yuan Z, Hao J (2014). Prostate-specific membrane antigen as a marker of pancreatic cancer cells. Med Oncol 31: 1–6.
176. Resnick MJ, Koyama T, Fan K-H, Albertsen PC, Goodman M, Hamilton AS et al. (2013). Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368: 436–445.
177. Riveros N, Orrego F (1984). A study of possible excitatory effects of N-acetylaspartylglutamate in different in vivo and in vitro brain preparations. Brain Res 299: 393–395.
178. Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA (2015). Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst 107: dju503.
179. Robinson MB, Blakely R, Couto R, Coyle J (1987). Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 262: 14498–14506.
180. Romei C, Raiteri M, Raiteri L (2013). Glycine release is regulated by metabotropic glutamate receptors sensitive to mGluR2/3 ligands and activated by N-acetylaspartylglutamate (NAAG). Neuropharmacology 66: 311–316.
181. Rowdo FPM, Baron A, Urrutia M, Mordoh J (2015). Immunotherapy in cancer: a combat between tumors and the immune system; you win some, you lose some. Front Immunol 6: 127.
182. Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N et al. (2015). 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med 56: 1003–1010.
183. Roy J, Nguyen TX, Kanduluru AK, Venkatesh C, Lv W, Reddy PN et al. (2015). DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase i inhibitor for selective prostate cancer cell targeting. J Med Chem 58: 3094–3103.
184. Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH et al. (2011). Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med 52: 1608–1615.
185. Šácha P, Zámečník J, Bařinka C, Hlouchova K, Vicha A, Mlčochová P et al. (2007). Expression of glutamate carboxypeptidase II in human brain. Neuroscience 144: 1361–1372.
186. Samplaski MK, Heston W, Elson P, Magi-Galluzzi C, Hansel DE (2011). Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Mod Pathol 24: 1521–1529.
187. Sanabria ERG, Wozniak KM, Slusher BS, Keller A (2004). GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism. J Neurophysiol 91: 182–193.
188. Sanna V, Pintus G, Roggio AM, Punzoni S, Posadino AM, Arca A et al. (2011). Targeted biocompatible nanoparticles for the delivery of (−)-epigallocatechin 3-gallate to prostate cancer cells. J Med Chem 54: 1321–1332.
189. Santoro S, Kim S, Motz G, Alatzoglou D, Li C, Irving M et al. (2014). T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer Immunol Res 3: 68–84.
190. Schäfer M, Bauder-Wüst U, Leotta K, Zoller F, Mier W, Haberkorn U et al. (2012). A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res 2: 23.
191. Schiavina R, Ceci F, Romagnoli D, Uprimny C, Brunocilla E, Borghesi M et al. (2015). 68 Ga-PSMA PET/CT-guided salvage retroperitoneal lymph node dissection for disease relapse after radical prostatectomy for prostate cancer. Clin Genitourin Cancer 13: e415–e417.
192. Schwenck J, Tabatabai G, Skardelly M, Reischl G, Beschorner R, Pichler B et al. (2015). In vivo visualization of prostate-specific membrane antigen in glioblastoma. Eur J Nucl Med Mol Imaging 42: 170–171.
193. Shafizadeh TB, Halsted CH (2007). γ-Glutamyl hydrolase, not glutamate carboxypeptidase II, hydrolyzes dietary folate in rat small intestine. J Nutr 137: 1149–1153.
194. Shallal HM, Minn I, Banerjee SR, Lisok A, Mease RC, Pomper MG (2014). Heterobivalent Agents Targeting PSMA and Integrin-αvβ3. Bioconjug Chem 25: 393–405.
195. Shippenberg TS, Rea W, Slusher BS (2000). Modulation of behavioral sensitization to cocaine by NAALADase inhibition. Synapse 38: 161–166.
196. Shuba Y, Prevarskaya N, Lemonnier L, Van Coppenolle F, Kostyuk P, Mauroy B et al. (2000). Volume-regulated chloride conductance in the LNCaP human prostate cancer cell line. Am J Physiol Cell Physiol 279: C1144–C1154.
197. Simone CB, Hahn SM (2013). What's in a Label? Radioimmunotherapy for Metastatic Prostate Cancer. Clin Cancer Res 19: 4908–4910.
198. Slusher BS, Thomas A, Paul M, Schad CA, Ashby CR (2001). Expression and acquisition of the conditioned place preference response to cocaine in rats is blocked by selective inhibitors of the enzyme N-acetylated-α-linked-acidic dipeptidase (NAALADASE). Synapse 41: 22–28.
199. Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Harukuni I, Bhardwaj A et al. (1999). Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 5: 1396–1402.
200. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D et al. (2000). In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 60: 5237–5243.
201. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS guide to pHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054–D1068.
202. Strebhardt K, Ullrich A (2006). Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6: 321–330.
203. Su Y, Yu L, Liu N, Guo Z, Wang G, Zheng J et al. (2013). PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth. Cancer Lett 338: 282–291.
204. Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y (2014a). Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids 3: e182.
205. Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y (2014b). Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed 53: 12320–12364.
206. Sutradhar KB, Amin ML (2014). Nanotechnology in cancer drug delivery and selective targeting. ISRN Nanotechnol 2014. doi:10.1155/2014/939378.
207. Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH et al. (2013). Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 19: 5182–5191.
208. Taghdisi SM, Danesh NM, Sarreshtehdar Emrani A, Tabrizian K, ZandKarimi M, Ramezani M et al. (2013). Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer. J Drug Target 21: 739–744.
209. Takeshita F, Patrawala L, Osaki M, Takahashi R-U, Yamamoto Y, Kosaka N et al. (2010). Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18: 181–187.
210. Tallarida C, Song K, Raffa RB, Rawls SM (2012). Glutamate carboxypeptidase II (GCPII) inhibitor displays anti-glutamate and anti-cocaine effects in an invertebrate assay. Amino Acids 42: 2521–2524.
211. Tang L, Tong R, Coyle VJ, Yin Q, Pondenis H, Borst LB et al. (2015). Targeting tumor vasculature with aptamer-functionalized doxorubicin–polylactide nanoconjugates for enhanced cancer therapy. ACS Nano 9: 5072–5081.
212. Taylor RM, Huber DL, Monson TC, Ali A-MS, Bisoffi M, Sillerud LO (2011). Multifunctional iron platinum stealth immunomicelles: targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging. J Nanopart Res 13: 4717–4729.
213. Thakker D, Natt F, Huesken D, Van Der Putten H, Maier R, Hoyer D et al. (2005). siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol Psychiatry 10: 782–789.
214. Thariat J, Hannoun-Levi J-M, Myint AS, Vuong T, Gérard J-P (2013). Past, present, and future of radiotherapy for the benefit of patients. Nat Rev Clin Oncol 10: 52–60.
215. Thomas AG, Liu W, Olkowski JL, Tang Z, Lin Q, Lu X-CM et al. (2001). Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-β. Eur J Pharmacol 430: 33–40.
216. Tolmachev V, Malmberg J, Estrada S, Eriksson O, Orlova A (2014). Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution. Int J Oncol 44: 1998–2008.
217. Tong R, Coyle VJ, Tang L, Barger AM, Fan TM, Cheng J (2010). Polylactide nanoparticles containing stably incorporated cyanine dyes for in vitro and in vivo imaging applications. Microsc Res Tech 73: 901–909.
218. Tortella FC, Lin Y, Ved H, Slusher BS, Dave JR (2000). Neuroprotection produced by the NAALADase inhibitor 2-PMPA in rat cerebellar neurons. Eur J Pharmacol 402: 31–37.
219. Tse BW-C, Cowin GJ, Soekmadji C, Jovanovic L, Vasireddy RS, Ling M-T et al. (2015). PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine 10: 375–386.
220. Tsukamoto T, Wozniak KM, Slusher BS (2007). Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today 12: 767–776.
221. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH (2005). Radioimmunotherapy of prostate cancer using 90Y-and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res 11: 7195s–7200s.
222. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH (2004). Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate 58: 145–155.
223. Van der Post J, De Visser S, De Kam M, Woelfler M, Hilt D, Vornov J et al. (2005). The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. Br J Clin Pharmacol 60: 128–136.
224. Vittes GE, Harden EL, Ottensmeier CH, Rice J, Stevenson FK (2011). DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen. Eur J Immunol 41: 2447–2456.
225. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Böhme C, Schmid H-P et al. (2006). Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 55: 1524–1533.
226. Wang H-l, Wang S-s, Song W-H, Pan Y, Yu H-p, Si T-G et al. (2015). Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS One 10: e0125924.
227. Wang H, Byun Y, Barinka C, Pullambhatla M, Hyo-eun CB, Fox JJ et al. (2010). Bioisosterism of urea-based GCPII inhibitors: synthesis and structure–activity relationship studies. Bioorg Med Chem Lett 20: 392–397.
228. Wang X, Huang SS, Heston WD, Guo H, Wang B-C, Basilion JP (2014). Development of targeted near-infrared imaging agents for prostate cancer. Mol Cancer Ther 13: 2595–2606.
229. Wang X, Ma D, Olson WC, Heston WD (2011). In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther 10: 1728–1739.
230. Watanabe R, Sato K, Hanaoka H, Harada T, Nakajima T, Kim I et al. (2014). Minibody-indocyanine green based activatable optical imaging probes: the role of short polyethylene glycol linkers. ACS Med Chem Lett 5: 411–415.
231. Watt F, Martorana A, Brookes DE, Ho T, Kingsley E, O'Keefe DS et al. (2001). A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics 73: 243–254.
232. Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S et al. (2015). 68Ga-and 177Lu-Labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56: 1169–1176.
233. Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester H-J (2014). Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res 1: 1–15.
234. Wernicke AG, Varma S, Greenwood EA, Christos PJ, Chao K, Liu H et al. (2014). Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS 122: 482–489.
235. Wiehr S, Bühler P, Gierschner D, Wolf P, Rolle AM, Kesenheimer C et al. (2014). Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody. Prostate 74: 743–755.
236. Williams BJ, Bhatia S, Adams LK, Boling S, Carroll JL, Li X-L et al. (2012). Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector. PLoS One 7: e46981.
237. Williamson LC, Neale JH (1988). Ultrastructural localization of N-acetylaspartylglutamate in synaptic vesicles of retinal neurons. Brain Res 456: 375–381.
238. Wissenbach U, Niemeyer BA, Fixemer T, Schneidewind A, Trost C, Cavalié A et al. (2001). Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer. J Biol Chem 276: 19461–19468.
239. Witkin JM, Gasior M, Schad C, Zapata A, Shippenberg T, Hartman T et al. (2002). NAALADase (GCP II) inhibition prevents cocaine-kindled seizures. Neuropharmacology 43: 348–356.
240. Wright AS, Thomas LN, Douglas RC, Lazier CB, Rittmaster RS (1996). Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest 98: 2558.
241. Wu LY, Johnson JM, Simmons JK, Mendes DE, Geruntho JJ, Liu T et al. (2014). Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells. Prostate 74: 451–457.
242. Wu X, Ding B, Gao J, Wang H, Fan W, Wang X et al. (2011). Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomedicine 6: 1747.
243. Wu Z-M, Zheng C-H, Zhu Z-H, Wu F-T, Ni G-L, Liang Y (2016). SiRNA-mediated serotonin transporter knockdown in the dorsal raphe nucleus rescues single prolonged stress-induced hippocampal autophagy in rats. J Neurol Sci 360: 133–140.
244. Xi H-B, Wang G-X, Fu B, Liu W-P, Li Y (2015). Survivin and PSMA loaded dendritic cell vaccine for the treatment of Prostate Cancer. Biol Pharm Bull 38: 827–835.
245. Xi Z-X, Kiyatkin M, Li X, Peng X-Q, Wiggins A, Spiller K et al. (2010a). N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats. Neuropharmacology 58: 304–313.
246. Xi ZX, Li X, Peng XQ, Li J, Chun L, Gardner EL et al. (2010b). Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism. J Neurochem 112: 564–576.
247. Xiang B, Dong D-W, Shi N-Q, Gao W, Yang Z-Z, Cui Y et al. (2013). PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer. Biomaterials 34: 6976–6991.
248. Xu W, Siddiqui IA, Nihal M, Pilla S, Rosenthal K, Mukhtar H et al. (2013). Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials 34: 5244–5253.
249. Yallapu MM, Khan S, Maher DM, Ebeling MC, Sundram V, Chauhan N et al. (2014). Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials 35: 8635–8648.
250. Yamamoto T, Hirasawa S, Wroblewska B, Grajkowska E, Zhou J, Kozikowski A et al. (2004). Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. Eur J Neurosci 20: 483–494.
251. Yamamoto T, Kozikowski A, Zhou J, Neale JH (2008). Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain. Mol Pain 4: 1.
252. Yamamoto T, Nozaki-Taguchi N, Sakashita Y (2001a). Spinal N-acetyl-α-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Res 909: 138–144.
253. Yamamoto T, Nozaki-Taguchi N, Sakashita Y, Inagaki T (2001b). Inhibition of spinal N-acetylated-α-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test. Neuroscience 102: 473–479.
254. Yamamoto T, Saito O, Aoe T, Bartolozzi A, Sarva J, Zhou J et al. (2007). Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. Eur J Neurosci 25: 147–158.
255. Yao V, Bacich DJ (2006). Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. Prostate 66: 867–875.
256. Yao V, Berkman CE, Choi JK, O'Keefe DS, Bacich DJ (2010a). Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate 70: 305–316.
257. Yao V, Berkman CE, Choi JK, O'Keefe DS, Bacich DJ (2010b). Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate 70: 305–316.
258. Yao V, Parwani A, Maier C, Heston WD, Bacich DJ (2008). Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res 68: 9070–9077.
259. Youlin K, Li Z, Xin G, Mingchao X, Xiuheng L, Xiaodong W (2013). Enhanced function of cytotoxic T lymphocytes induced by dendritic cells modified with truncated PSMA and 4-1BBL. Hum Vaccines Immunother 9: 766–772.
260. Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C et al. (2014). Therapeutic bispecific antibodies cross the blood–brain barrier in nonhuman primates. Sci Transl Med 6: 261ra154–261ra154.
261. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B et al. (2014). Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 41: 1280–1292.
262. Zhang Y, Guo Z, Du T, Chen J, Wang W, Xu K et al. (2013). Prostate specific membrane antigen (PSMA): a novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells. Prostate 73: 835–841.
263. Zhao J, Ramadan E, Cappiello M, Wroblewska B, Bzdega T, Neale JH (2001). NAAG inhibits KCl-induced [3H]-GABA release via mGluR3, cAMP, PKA and L-type calcium conductance. Eur J Neurosci 13: 340–346.
264. Zhao R, Matherly LH, Goldman ID (2009). Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 11: e4.
265. Zhao Y, Duan S, Zeng X, Liu C, Davies NM, Li B et al. (2012). Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm 9: 1705–1716.
266. Zhong C, Luo Q, Jiang J (2014). Blockade of N-acetylaspartylglutamate peptidases: a novel protective strategy for brain injuries and neurological disorders. Int J Neurosci 124: 867–873.
267. Zhong C, Zhao X, Sarva J, Kozikowski A, Neale JH, Lyeth BG (2005). NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats. J Neurotrauma 22: 266–276.
268. Zhong C, Zhao X, Van KC, Bzdega T, Smyth A, Zhou J et al. (2006). NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. J Neurochem 97: 1015–1025.
269. Zhou Z, Lane MV, Kemppainen JA, French FS, Wilson EM (1995). Specificity of ligand-dependent androgen receptor stabilization: Receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 9: 208–218.
270. Zhu Y, Sun Y, Chen Y, Liu W, Jiang J, Guan W et al. (2015). In vivo molecular MRI imaging of prostate cancer by targeting PSMA with polypeptide-labeled superparamagnetic iron oxide nanoparticles. Int J Mol Sci 16: 9573–9587.
271. Zuccolotto G, Fracasso G, Merlo A, Montagner IM, Rondina M, Bobisse S et al. (2014). PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models.
272. Zuo D, Wang C, Li Z, Lin L, Duan Z, Qi H et al. (2014). Existence of glia mitigated ketamine-induced neurotoxicity in neuron–glia mixed cultures of neonatal rat cortex and the glia-mediated protective effect of 2-PMPA. Neurotoxicology 44: 218–230.